Soteria Biotherapeutics is developing switchable bispecific T-cell engagers using its T-LITE™ platform to treat solid tumors in cancer patients. This technology enables pulsatile activation of antibody therapies, resulting in safer treatments with reduced side effects and improved dosing efficacy.
Funding
$42M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
RVFounders
Product
Problem
Existing bispecific T-cell engager therapies for solid tumors can cause significant side effects due to continuous T-cell activation, limiting dosing and efficacy. This toxicity stems from the inability to precisely control the duration and intensity of T-cell engagement, leading to off-target effects and systemic immune activation.
Solution
Soteria Biotherapeutics is developing switchable bispecific T-cell engagers that use its T-LITE™ platform to enable pulsatile activation of antibody therapies. This approach allows for controlled, intermittent engagement of T-cells with tumor cells, reducing off-target toxicity and improving the therapeutic window. By precisely modulating T-cell activity, the T-LITE™ platform aims to deliver safer and more efficacious treatments for patients with solid tumor cancers. The technology enables higher dosing and reduced side effects compared to traditional bispecific T-cell engagers.
Target Audience
The primary target audience includes cancer patients with solid tumors who may benefit from safer and more effective bispecific T-cell engager therapies, as well as oncologists and researchers focused on immuno-oncology treatments.
Features
- T-LITE™ platform for switchable activation of bispecific antibody therapies
- Pulsatile T-cell activation to minimize off-target toxicity
- Enhanced dosing capabilities due to improved safety profile
- Bispecific engagers designed to target specific solid tumor antigens